Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised to reshape drug development.
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
3 key ways AI-powered analysis supports drug development
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
5 guardrails you MUST implement when using AI in biopharma
Implementing guardrails for artificial intelligence (AI) in the biopharmaceutical industry is crucial for ensuring effective, safe, and compliant use of this powerful technology.
Biotech Limited Partners: learnings from investing in biotech venture capital funds
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
What causes AI hallucinations & how Vibe Bio delivers results you can trust
Artificial Intelligence (AI) is a broad umbrella of technologies, covering a huge swathe of algorithmic applications.
Enabling every cure for community matters: Our AI-powered journey
As we move through 2024, I’m thrilled with the extraordinary work our team is doing to change how we finance drug development: from funding next-generation therapies to helping others identify the highest potential cures in their development pipelines.
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence.
